Bio

Honors & Awards


  • New Investigator Award, American Society for Blood and Marrow Transplantation (2015)
  • Best Abstract Award for Basic Science Research, American Society for Blood and Marrow Transplantation (2014)
  • Dr. Mildred Scheel Postdoctoral Fellowship, Deutsche Krebshilfe (2012)

Professional Education


  • Postdoctoral Research Fellow, Stanford University, Bone Marrow Transplantation (2012)
  • Residency, Eberhard Karls University of Tübingen, Internal Medicine (2010)
  • Doctor of Medicine, Universitat Ulm (2010)

Stanford Advisors


Research & Scholarship

Current Research and Scholarly Interests


Specific areas of active research include immunoregulation and immunologic reconstitution following allogeneic hematopoietic cell transplantation (HCT) to develop novel adoptive transfer strategies which induce immunologic tolerance, prevent graft-versus-host disease (GVHD), and augment graft-versus-tumor (GVT) effects to cure cancer.

Publications

Journal Articles


  • Third party CD4+ invariant natural killer T cells protect from murine GVHD lethality. Blood Schneidawind, D., Baker, J., Pierini, A., Buechele, C., Luong, R. H., Meyer, E. H., Negrin, R. S. 2015

    Abstract

    Graft-versus-host disease (GVHD) is driven by extensive activation and proliferation of alloreactive donor T cells causing significant morbidity and mortality following allogeneic hematopoietic cell transplantation (HCT). Invariant natural killer T (iNKT) cells are a potent immunoregulatory T-cell subset in both humans and mice. Here, we explored the role of adoptively transferred third party CD4(+) iNKT cells for protection from lethal GVHD in a murine model of allogeneic HCT across major histocompatibility barriers. We found that low numbers of CD4(+) iNKT cells from third party mice resulted in a significant survival benefit with retained graft-versus-tumor (GVT) effects. In vivo expansion of alloreactive T cells was diminished while displaying a Th2-biased phenotype. Notably, CD4(+) iNKT cells from third party mice were as protective as CD4(+) iNKT cells from donor mice although third party CD4(+) iNKT cells were rejected early after allogeneic HCT. Adoptive transfer of third party CD4(+) iNKT cells resulted in a robust expansion of donor CD4(+)CD25(+)FoxP3(+) regulatory T cells (Tregs) that were required for protection from lethal GVHD. However, in vivo depletion of myeloid-derived suppressor cells (MDSCs) abrogated both Treg expansion and protection from lethal GVHD. Despite the fact that iNKT cells are a rare cell population, the almost unlimited third party availability and feasibility of in vitro expansion provide the basis for clinical translation.

    View details for DOI 10.1182/blood-2014-11-612762

    View details for PubMedID 25795920

  • CD4+ invariant natural killer T cells protect from murine GVHD lethality through expansion of donor CD4+CD25+FoxP3+ regulatory T cells. Blood Schneidawind, D., Pierini, A., Alvarez, M., Pan, Y., Baker, J., Buechele, C., Luong, R. H., Meyer, E. H., Negrin, R. S. 2014; 124 (22): 3320-3328

    Abstract

    Dysregulated donor T cells lead to destruction of host tissues resulting in graft-versus-host disease (GVHD) after allogeneic hematopoietic cell transplantation (HCT). We investigated the impact of highly purified (>95%) donor CD4(+) invariant natural killer T (iNKT) cells on GVHD in a murine model of allogeneic HCT. We found that low doses of adoptively transferred donor CD4(+) iNKT cells protect from GVHD morbidity and mortality through an expansion of donor CD4(+)CD25(+)FoxP3(+) regulatory T cells (Treg). These Treg express high levels of the Ikaros transcription factor Helios and expand from the Treg pool of the donor graft. Furthermore, CD4(+) iNKT cells preserve T cell-mediated graft-versus-tumor (GVT) effects. Our studies reveal new aspects of the cellular interplay between iNKT cells and Treg in the context of tolerance induction after allogeneic HCT and set the stage for clinical translation.

    View details for DOI 10.1182/blood-2014-05-576017

    View details for PubMedID 25293774

  • Regulatory T cells and natural killer T cells for modulation of GVHD following allogeneic hematopoietic cell transplantation BLOOD Schneidawind, D., Pierini, A., Negrin, R. S. 2013; 122 (18): 3116-3121

    Abstract

    Alloreactivity of donor lymphocytes leads to graft-versus-host disease (GVHD) contributing to significant morbidity and mortality following allogeneic hematopoietic cell transplantation (HCT). Within the past decade, significant progress has been made in elucidating the mechanisms underlying the immunologic dysregulation characteristic of GVHD. The recent discoveries of different cell subpopulations with immune regulatory function has led to a number of studies aimed at understanding their role in allogeneic HCT and possible application for the prevention and treatment of GVHD and a host of other immune-mediated diseases. Preclinical animal modeling has helped define the potential roles of distinct populations of regulatory cells that have progressed to clinical translation with promising early results.

    View details for DOI 10.1182/blood-2013-08-453126

    View details for Web of Science ID 000326503200010

    View details for PubMedID 24068494

  • Autologous apoptotic cells preceding transplantation enhance survival in lethal murine graft-versus-host models BLOOD Florek, M., Sega, E. I., Leveson-Gower, D. B., Baker, J., Mueller, A. M., Schneidawind, D., Meyer, E., Negrin, R. S. 2014; 124 (11): 1832-1842
  • Role of Lymphocyte Activation Gene-3 (Lag-3) in Conventional and Regulatory T Cell Function in Allogeneic Transplantation PLOS ONE Sega, E. I., Leveson-Gower, D. B., Florek, M., Schneidawind, D., Luong, R. H., Negrin, R. S. 2014; 9 (1)
  • Allogeneic hematopoietic cell transplantation with reduced-intensity conditioning following FLAMSA for primary refractory or relapsed acute myeloid leukemia. Annals of hematology Schneidawind, D., Federmann, B., Faul, C., Vogel, W., Kanz, L., Bethge, W. A. 2013

    Abstract

    Patients with primary refractory or relapsed acute myeloid leukemia (AML) have a dismal prognosis. We report a retrospective single center analysis of aplasia-inducing chemotherapy using fludarabine, cytarabine, and amsacrine (FLAMSA) followed by reduced-intensity conditioning (RIC) for allogeneic hematopoietic cell transplantation (HCT) in 62 consecutive primary refractory or relapsed AML patients. Two-year event-free survival and overall survival (OS) were 26 and 39 %, respectively. Risk stratification according to cytogenetic and molecular genetic markers showed superior survival in patients in the intermediate-1 risk group (2-year OS 70 %) compared to the intermediate-2 risk (2-year OS 34 %, p?=?0.03) and adverse risk (2-year OS 38 %, p?=?0.06) group. The use of HLA-matched versus HLA-mismatched donors had no significant influence on survival (p?=?0.98). Two-year OS in the elderly subgroup defined by age ?60 years was 31 % compared to 46 % in the group of younger patients <60 years (p?=?0.19). Cumulative incidence of non-relapse mortality at 2 years adjusted for relapse as competing risk was 20 % for patients <60 years and 26 % for older patients (p?=?0.55). Chronic graft-versus-host disease was associated with a statistically significant superior survival (p?

    View details for PubMedID 23652585

  • Allogeneic hematopoietic cell transplantation in patients with acute myeloid leukemia and pulmonary mucormycosis TRANSPLANT INFECTIOUS DISEASE Schneidawind, D., Nann, D., Vogel, W., Faul, C., Fend, F., Horger, M., Kanz, L., Bethge, W. 2012; 14 (6): E166-E172

    Abstract

    Mucormycosis is a serious invasive fungal infection in immunocompromised patients. Patients undergoing treatment for hematologic malignancies are predominantly prone to the pulmonary manifestation of mucormycosis. Historically, allogeneic hematopoietic cell transplantation (HCT) in patients suffering from pulmonary mucormycosis (PM) was considered contraindicated owing to mortality rates up to 90%. We present 3 patients with acute myeloid leukemia and PM who were treated with radical surgical debridement combined with high-dose liposomal amphotericin B (LAB), and subsequently underwent successful allogeneic HCT. To date, all 3 patients are in complete remission and show no signs of mucormycosis. Allogeneic HCT in patients with PM seems feasible provided that the infectious focus is completely removed surgically and adequate antifungal pharmacotherapy, such as high-dose LAB or posaconazole, is established.

    View details for DOI 10.1111/tid.12019

    View details for Web of Science ID 000312149100009

    View details for PubMedID 23075207

  • [Allogeneic stem cell transplantation for acute myeloid leukemia and HIV infection--case 3/2012]. Deutsche medizinische Wochenschrift Schneidawind, D., Dorn, C., Faul, C., Vogel, W., Berg, C., Beck, R., Korn, K., Dittmann, H., Schleicher, J., Erbersdobler, A., Jahn, G., Kanz, L., Bethge, W. 2012; 137 (10): 495-?

    Abstract

    HISTORY AND ADMISSION FINDINGS: A 27-year-old male patient with a past medical history of HIV presented with acute myeloid leukemia for allogeneic hematopoietic stem cell transplantation (HSCT). Highly active anti-retroviral therapy suppressed the viral load below detection threshold. INVESTIGATIONS: There were no contraindications for allogeneic HSCT. TREATMENT AND COURSE: Myeloablative conditioning consisted of total body irradiation and cyclophosphamide. Anti-thymocyte globulin, tacrolimus and mycophenolate mofetil were used for immunosuppression. Combined anti-retroviral therapy (nucleoside and nucleotide analog reverse-transcriptase inhibitor, boostered protease inhibitor, maraviroc and raltegravir) was maintained for allogeneic HSCT and viral load remained below detection threshold. No graft-versus-host disease or serious infectious complications occurred. The patient showed good graft function with stable hematopoiesis. Localized Kaposi's sarcoma was diagnosed six months after allogeneic HSCT and treated successfully with surgical excision and reduction of immunosuppression. Almost one year after allogeneic HSCT, the CD4+ cell count is rising and viral load remains below detection threshold with combined anti-retroviral therapy. Conclusion: Allogeneic HSCT can be safely performed in HIV positive patients. Kaposi's sarcoma is a rare event after allogeneic HSCT and linked to strong immunosuppression.

    View details for DOI 10.1055/s-0031-1299022

    View details for PubMedID 22374660

  • Polyomavirus BK-specific CD8+T cell responses in patients after allogeneic stem cell transplant LEUKEMIA & LYMPHOMA Schneidawind, D., Schmitt, A., Wiesneth, M., Mertens, T., Bunjes, D., Freund, M., Schmitt, M. 2010; 51 (6): 1055-1062

    Abstract

    Polyomavirus BK (BKV) is known as an important etiologic agent in the development of hemorrhagic cystitis (HC) after allogeneic stem cell transplant (SCT). To define T cell epitopes of the BKV proteins VP1 and sT, eight potential HLA-A2-binding peptides were synthesized based on computer algorithms. These peptides were co-incubated with CD8 + T cells from the peripheral blood (PB) of 25 healthy volunteers and seven patients suffering from HC after allogeneic SCT in a mixed-lymphocyte peptide culture (MLPC), which were subsequently screened by enzyme-linked immunospot (ELISPOT) assays and fluorescence-activated cell sorting (FACS) analysis. We found that CD8 + T cells from five of seven (71%) patients with HC presensitized with the BKV peptide VP1 p108 (LLMWEAVTV) specifically recognized T2 cells pulsed with VP1 p108. In contrast, only seven of 25 (28%) healthy volunteers had CD8 + T cells reactive with VP1 p108-pulsed T2 cells. The presence of VP1 p108-specific T cells could be confirmed by FACS analysis. The BKV peptide VP1 p108 seems to play an important role as an immunodominant peptide in the pathogenesis of HC in patients after allogeneic SCT, and might be a promising target for immunotherapies or even strategies to prevent the development of BKV-associated HC.

    View details for DOI 10.3109/10428191003746323

    View details for Web of Science ID 000279485300016

    View details for PubMedID 20370539

Books and Book Chapters


  • Ionisierende Strahlung (Schneidawind D.) Erste Hilfe – Physik und Chemie für Mediziner Schatz, J., Tammer, R. Springer. 2007

Stanford Medicine Resources: